BLA 761068 · Kyowa Kirin
Crysvita
Burosumab-Twza · Injection
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Apr 17, 2018
Approved uses
5
Original approval plus efficacy supplements
Registered trials
26
8 Phase 3, 2 recruiting
FAERS reports
6,487
1,394 serious, 43 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 22, 2026.
CRYSVITA is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for: The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older. ( 1.1 ) The treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older. ( 1.2 ) 1.1 X-linked Hypophosphatemia CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older. 1.2 Tumor-induced Osteomalacia CRYSVITA is indicated for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.
Mechanism: X-linked hypophosphatemia is caused by excess fibroblast growth factor 23 (FGF23) which suppresses renal tubular phosphate reabsorption and the renal production of 1,25 dihydroxy vitamin D. Burosumab-twza binds to and inhibits the biological activity of FGF23 restoring renal phosphate reabsorption and increasing the serum concentration of 1,25 dihydroxy vitamin D.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 23, 2026 Supplement 11 · Efficacy OrphanLabelLetter
- Jun 18, 2020 Supplement 5 · Efficacy · priority review OrphanLetterLabel
- Sep 27, 2019 Supplement 3 · Efficacy OrphanLetterLabel
- Sep 27, 2019 Supplement 4 · Efficacy · priority review OrphanLetterLabel
- Apr 17, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- CRYSVITA · BUROSUMAB-TWZA 10MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Burosumab" as an intervention, any sponsor and status, largest first.
- Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)Pivotal-lookingCompleted
Kyowa Kirin, Inc.Industry
NCT02526160 · 134 participants · Start Oct 22, 2015 · Primary completion Dec 22, 2016
Drug: burosumab · For: X-linked Hypophosphatemia
Sites: Los Angeles, California; San Francisco, California; New Haven, Connecticut · 25 sites in all
- Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLHPivotal-lookingCompleted
Kyowa Kirin, Inc.Industry
NCT02915705 · 61 participants · Start Sep 8, 2016 · Primary completion Feb 12, 2018
Drug: burosumab; Oral Phosphate Supplement and 1 more · For: X-Linked Hypophosphatemia
Sites: Los Angeles, California; San Francisco, California; Indianapolis, Indiana · 16 sites in all
Bicetre HospitalAcademic, hospital or other
NCT04419363 · 57 participants (planned) · Start Mar 18, 2018 · Primary completion Mar 20, 2019
Drug: Burosumab Injection · For: Rare Diseases; X-linked Hypophosphatemia
Sites: Le Kremlin-Bicêtre, France
Kyowa Kirin, Inc.Industry
NCT02163577 · 52 participants · Start Jul 2, 2014 · Primary completion Oct 30, 2018
Drug: burosumab · For: X-linked Hypophosphatemia
Sites: San Francisco, California; New Haven, Connecticut; Indianapolis, Indiana · 9 sites in all
Kyowa Kirin Co., Ltd.Industry
NCT00830674 · 42 participants · Start Dec 2008 · Primary completion Dec 2011
Drug: Placebo; KRN23 · For: X-linked Hypophosphatemia
Sites: New Haven, Connecticut; Indianapolis, Indiana; Durham, North Carolina · 4 sites in all
- Anti-FGF23 (Burosumab) in Adult Patients With XLHPivotal-lookingCompleted
Wuerzburg University HospitalAcademic, hospital or other
NCT04695860 · 36 participants · Start Jan 7, 2021 · Primary completion Mar 17, 2023
Drug: Burosumab · For: X-linked Hypophosphatemia
Sites: Würzburg, Germany
- Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLHPivotal-lookingCompleted
Kyowa Kirin Pharmaceutical Development LtdIndustry
NCT03920072 · 35 participants · Start Mar 7, 2019 · Primary completion Apr 7, 2022
Drug: Burosumab · For: X-linked Hypophosphatemia
Sites: Le Kremlin-Bicêtre, France; Paris, France; Dublin, Ireland · 10 sites in all
Kyowa Kirin Co., Ltd.Industry
NCT01340482 · 29 participants · Start Apr 2011 · Primary completion May 2013
Drug: KRN23 · For: X-linked Hypophosphatemia
Sites: San Francisco, California; New Haven, Connecticut; Indianapolis, Indiana · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- inappropriate schedule of product administration719
- product dose omission issue677
- blood phosphorus decreased584
- pain408
- arthralgia385
- pain in extremity364
- restless legs syndrome284
- headache282
- fatigue260
- incorrect dose administered258
- injection site pain246
- bone pain216
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 117 |
| 2019 | 801 |
| 2020 | 1,134 |
| 2021 | 1,266 |
| 2022 | 1,336 |
| 2023 | 417 |
| 2024 | 454 |
| 2025 | 493 |
| 2026 | 469 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Crysvita (Burosumab-Twza)
2024 spending
$55.9M
Beneficiaries
179
2,127 claims
Per beneficiary
$312,265
$11,196.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $18,706,131 |
| 2021 | $24,890,865 |
| 2022 | $31,146,027 |
| 2023 | $38,599,104 |
| 2024 | $55,895,510 |
Part B: Crysvita (Burosumab-Twza) · HCPCS J0584
2024 spending
$24.2M
Beneficiaries
81
801 claims
Per beneficiary
$298,435
2024 ASP limit $456.42 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,867,168 |
| 2021 | $14,295,749 |
| 2022 | $20,535,356 |
| 2023 | $22,460,838 |
| 2024 | $24,173,202 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment.
Kamenicky P, Briot K, Brandi ML, et al. · RMD Open 2023 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
Imel EA, Glorieux FH, Whyte MP, et al. · Lancet 2019 · Clinical Trial, Phase III, Comparative Study
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Insogna KL, Briot K, Imel EA, et al. · J Bone Miner Res 2018 · Clinical Trial, Phase III, Randomized Controlled Trial
- Meta-analysis and systematic review: burosumab as a promising treatment for children with X-linked hypophosphatemia.
Wang K, Zhang R, Chen Z, et al. · Front Endocrinol (Lausanne) 2024 · Systematic Review, Meta-Analysis
- Burosumab for the Treatment of Tumor-Induced Osteomalacia.
Jan de Beur SM, Miller PD, Weber TJ, et al. · J Bone Miner Res 2021 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Burosumab in X-linked Hypophosphatemia.
Wang S, Wang X, He M, et al. · J Clin Endocrinol Metab 2023 · Meta-Analysis, Systematic Review
Sponsor: Kyowa Kirin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.